Advertisement
Advertisement
-
Business /

Markets

Related Topics:
Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

Pop Mart’s Merodi Hong Kong debut highlights challenges of sustaining IP success

Toymaker’s latest character launch draws tepid demand, raising questions about the company’s reliance on Labubu’s success.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW